Trial · NCT02210065
Autologous Cytomegalovirus (CMV)-Specific Cytotoxic T Cells for Cytomegalovirus (CMV) Reactivation
NCT02210065, Phase 2, Completed, M.D. Anderson Cancer Center; results first posted 2020-03-17
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Autologous Cytomegalovirus (CMV)-Specific Cytotoxic T Cells for Cytomegalovirus (CMV) Reactivation. Trials, record NCT02210065. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02210065
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Autologous Cytomegalovirus (CMV)-Specific Cytotoxic T Cells for Cytomegalovirus (CMV) Reactivation
- NCT number
- NCT02210065
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 6 participants, actual
- Lead sponsor
- M.D. Anderson Cancer Center
- Conditions
- Leukemia, Lymphoma
- Interventions
- Cytomegalovirus (CMV)-Specific Cytotoxic T Cells (CTLs)
- First posted
- 2014-08-06
- Last updated
- 2020-03-17
- Results first posted
- 2020-03-17
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants With Non-Relapse Mortality | 6 months | Non-relapse mortality defined as death because of causes other than relapse of the underlying hematological malignancy. |
| Primary | Success Rate of Cytotoxic T Cells | 28 days | Treatment considered a success if the patient does not require initiation of cytomegalovirus (CMV) anti-viral therapy. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants With Non-Relapse Mortality | 6 months | Participants | COUNT_OF_PARTICIPANTS | |
| PRIMARY | Success Rate of Cytotoxic T Cells | 28 days | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Non-Relapse Mortality | Cytomegalovirus (CMV)-Specific Cytotoxic T Cells (CTLs) | 0 | Participants | ||
| Success Rate of Cytotoxic T Cells | Cytomegalovirus (CMV)-Specific Cytotoxic T Cells (CTLs) | 1 | Participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Cytomegalovirus (CMV)-Specific Cytotoxic T Cells (CTLs) | 1 | |
| Overall Study | COMPLETED | Cytomegalovirus (CMV)-Specific Cytotoxic T Cells (CTLs) | 1 | |
| Overall Study | NOT COMPLETED | Cytomegalovirus (CMV)-Specific Cytotoxic T Cells (CTLs) | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Cytomegalovirus (CMV)-Specific Cytotoxic T Cells (CTLs) | 0 | 0 |
| Total, other adverse events | Cytomegalovirus (CMV)-Specific Cytotoxic T Cells (CTLs) | 0 | 0 |
| Total, serious adverse events | Cytomegalovirus (CMV)-Specific Cytotoxic T Cells (CTLs) | 0 | 0 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02210065
GET https://conductscience.org/api/trials/v1/NCT02210065/registered